CN1777807B - 利用角质形成细胞产生白介素18诱导现象阻碍剂的筛选方法及筛选试剂盒 - Google Patents

利用角质形成细胞产生白介素18诱导现象阻碍剂的筛选方法及筛选试剂盒 Download PDF

Info

Publication number
CN1777807B
CN1777807B CN2004800109935A CN200480010993A CN1777807B CN 1777807 B CN1777807 B CN 1777807B CN 2004800109935 A CN2004800109935 A CN 2004800109935A CN 200480010993 A CN200480010993 A CN 200480010993A CN 1777807 B CN1777807 B CN 1777807B
Authority
CN
China
Prior art keywords
mice
skin
cells
spa
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2004800109935A
Other languages
English (en)
Chinese (zh)
Other versions
CN1777807A (zh
Inventor
中西宪司
水谷仁
筒井博子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Science and Technology Agency
Original Assignee
Japan Science and Technology Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Science and Technology Agency filed Critical Japan Science and Technology Agency
Publication of CN1777807A publication Critical patent/CN1777807A/zh
Application granted granted Critical
Publication of CN1777807B publication Critical patent/CN1777807B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN2004800109935A 2003-04-24 2004-04-21 利用角质形成细胞产生白介素18诱导现象阻碍剂的筛选方法及筛选试剂盒 Expired - Fee Related CN1777807B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP120630/2003 2003-04-24
JP2003120630 2003-04-24
PCT/JP2004/005747 WO2004104578A1 (fr) 2003-04-24 2004-04-21 Methode de criblage d'inhibiteur par induction de la production d'interleukine 18 par les keratinocytes, methode d'induction du symptome similaire a la dermatite atopique et son utilisation

Publications (2)

Publication Number Publication Date
CN1777807A CN1777807A (zh) 2006-05-24
CN1777807B true CN1777807B (zh) 2011-05-25

Family

ID=33474677

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2004800109935A Expired - Fee Related CN1777807B (zh) 2003-04-24 2004-04-21 利用角质形成细胞产生白介素18诱导现象阻碍剂的筛选方法及筛选试剂盒

Country Status (8)

Country Link
US (2) US20070092448A1 (fr)
EP (2) EP2175270A1 (fr)
JP (1) JP4335211B2 (fr)
KR (2) KR20080049851A (fr)
CN (1) CN1777807B (fr)
AU (1) AU2004241513B2 (fr)
CA (2) CA2690035A1 (fr)
WO (1) WO2004104578A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8541240B2 (en) 2010-05-28 2013-09-24 Florida State University Research Foundation, Inc. Colorimetric and fluorimetric fluoride sensing
JP5520246B2 (ja) * 2011-02-25 2014-06-11 株式会社ファンケル アトピー性皮膚炎の検査方法
CN102818878B (zh) * 2012-06-18 2014-11-26 辉源生物科技（上海）有限公司 GHSR1a激动剂药物的筛选方法
FR3016170B1 (fr) * 2014-01-06 2020-05-08 Pierre Fabre Dermo-Cosmetique Procede d'obtention d'un modele cellulaire ou tissulaire representatif d'une peau fragile
CN105111300A (zh) * 2015-08-26 2015-12-02 中国检验检疫科学研究院 一种促进人角质细胞表达炎症因子IL-1α的方法
RU2694223C1 (ru) * 2018-12-29 2019-07-10 Федеральное государственное бюджетное образовательное учреждение высшего образования Читинская государственная медицинская академия Министерства здравоохранения российской федерации Способ прогнозирования риска развития инфекционных осложнений при атопическом дерматите

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001095710A1 (fr) * 2000-06-16 2001-12-20 Nakanishi, Kenji Animal transgenique porteur de caspase 1
JP2003038063A (ja) * 2001-07-30 2003-02-12 Kowa Co 皮膚炎発症ラット

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
郝飞.金黄色葡萄球菌感染与特应性皮炎.临床皮肤科杂志31 6.2002,31(6),402-404.
郝飞.金黄色葡萄球菌感染与特应性皮炎.临床皮肤科杂志31 6.2002,31(6),402-404. *

Also Published As

Publication number Publication date
EP1635176A4 (fr) 2006-10-04
KR20060011837A (ko) 2006-02-03
CN1777807A (zh) 2006-05-24
JPWO2004104578A1 (ja) 2006-07-20
US20070092448A1 (en) 2007-04-26
AU2004241513A1 (en) 2004-12-02
JP4335211B2 (ja) 2009-09-30
CA2690035A1 (fr) 2004-12-02
US8293212B2 (en) 2012-10-23
KR20080049851A (ko) 2008-06-04
WO2004104578A1 (fr) 2004-12-02
CA2523297C (fr) 2010-12-21
US20100003194A1 (en) 2010-01-07
EP1635176B1 (fr) 2013-05-22
CA2523297A1 (fr) 2004-12-02
EP2175270A1 (fr) 2010-04-14
EP1635176A1 (fr) 2006-03-15
AU2004241513B2 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
Van Den Bogaard et al. Crosstalk between keratinocytes and T cells in a 3D microenvironment: a model to study inflammatory skin diseases
Filbey et al. Macrophage migration inhibitory factor (MIF) is essential for type 2 effector cell immunity to an intestinal helminth parasite
Luo et al. Expression of IL-22, IL-22R and IL-23 in the peri-implant soft tissues of patients with peri-implantitis
US8293212B2 (en) Inhibitor screening method and atopic dermatitis like symptom inducing method which utilizes induction of production of interleukin 18 by keratinocyte and utilization of same
Nakano et al. Persistent secretion of IL‐18 in the skin contributes to IgE response in mice
Chiu et al. The innate pulmonary granuloma: characterization and demonstration of dendritic cell recruitment and function
Takenaka et al. Overexpression of phospholipase Cε in keratinocytes upregulates cytokine expression and causes dermatitis with acanthosis and T‐cell infiltration
AU2007242943B2 (en) Method of Screening Inhibitor by Using Induction of Interleukin 18 Production by Keratinocyte, Method of Inducing Atopic Dermatitis-Like Symptom and Utilization of the Same
Emancipator Prospects and perspectives on IgA nephropathy from animal models.
Pohlmeier Characterization of inflammatory responses in mouse models of asthma and wound healing
EP2913060A1 (fr) Inhibition de l'interaction de récepteur de fractalkine pour le traitement de la dermatite atopique
Bock Identification and characterization of murine and human Th2/1 hybrid cells in Th2-driven diseases
Zhang Investigating the role of CD109 in skin immune homeostasis and disease
Du Halgouet et al. Mechanisms Underlying Mait Cell Ability to Promote Skin Wound Repair
Price Investigations into the Cellular Sources of Type 2 Cytokines and Interleukin-17A using Cytokine Reporter Mice
Hanna et al. Intracellular Hedgehog signaling controls Th17 polarization and pathogenicity
Bernatchez CD103-mediated regulation of airway hypersensitivity responses to bioaerosol-associated antigens
Björnsdóttir The relationship of Calcitonin gene-related peptide (CGRP) and CGRP (8-37) to psoriasis
Rudikoff et al. Pathophysiology of atopic dermatitis and atopiform dermatitis
Berglund Intracellular regulation of TLR signaling Basic mechanisms and importance in intestinal inflammation
Krishnamurthy PARP14 in allergic inflammation
Wanke Regulation of Tight Junctions in Asthma
Newtown et al. Genomic approaches to the investigation of wound microbiology and pathogenesis
Towne et al. IL-1RL2 and Its Ligands Contribute to the
Baron et al. 33rd Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110525

Termination date: 20140421